KIF1Bβ通过转运和分泌FBLN5减弱整合素通路抑制肝细胞癌
本研究基于既往GWAS发现的1p36.22位点,在1934例病例和1446例对照中验证其与肝细胞癌风险相关(p=4.99×10-24),并确定KIF1Bβ为该位点靶基因。机制上KIF1Bβ与Fibulin-5相互作用,介导其胞内顺行转运和胞外分泌,从而减弱整合素通路激活;功能变异rs61784580位于KIF1Bβ启动子并等位基因特异性调控其表达,KIF1Bβ下调使肝癌细胞对整合素αv抑制剂西仑吉肽敏感。
要点
- 1p36.22位点与肝细胞癌风险显著相关,KIF1Bβ为其靶基因。
- KIF1Bβ通过转运分泌Fibulin-5减弱整合素通路,发挥抑癌作用。
- KIF1Bβ下调可增敏整合素αv抑制剂西仑吉肽。
核心结论
- KIF1Bβ是1p36.22位点的功能性靶基因,通过转运和分泌Fibulin-5减弱整合素通路而抑制肝细胞癌。
研究设计与样本
- 采用两个独立肝细胞癌病例对照人群,共1934例病例和1446例对照,验证1p36.22位点与肝癌风险的关联。
- 利用表达数量性状位点(eQTL)和eQTL-GWAS共定位分析鉴定1p36.22位点的靶基因。
- 在肝癌细胞、裸鼠模型和条件性敲除小鼠模型中评估靶基因对肿瘤发生的影响。
主要发现
- 证实1p36.22位点与肝细胞癌风险相关(p=4.99×10-24),并揭示该位点为KIF1Bβ基因的eQTL。
- 体外和体内实验证明KIF1Bβ在肝细胞癌中发挥抑癌作用。
- 机制上KIF1Bβ与货物蛋白Fibulin-5相互作用,介导其胞内顺行转运和胞外分泌,从而减少整合素通路激活。
- 鉴定出1p36.22位点的功能性致病变异rs61784580,位于KIF1Bβ启动子并等位基因特异性调控其表达。
- KIF1Bβ下调使肝癌细胞对整合素αv抑制剂西仑吉肽敏感。
临床怎么用
- KIF1Bβ表达下调的肝细胞癌患者可能对整合素αv抑制剂西仑吉肽治疗敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our previous genome-wide association study (GWAS) identified that chromosome 1p36.22 locus contributes to the risk of hepatocellular carcinoma (HCC). OBJECTIVE: We aimed to identify the functional causative variant(s) and target gene(s) at this locus. DESIGN: Two independent HCC case-control populations, totally consisting of 1934 cases and 1446 controls, were used to validate the association between 1p36.22 locus and HCC risk. The expression quantitative trait locus (eQTL) and eQTL-GWAS co-localisation analyses were used to identify the target gene at 1p36.22. The effects of the target gene on tumourigenesis were assessed in HCC cells, nude mouse models and conditional knockout mouse models. RESULTS: We confirmed the association between 1p36.22 locus and HCC risk (p=4.99×10-24), and revealed that this locus is an eQTL of the kinesin family member 1B isoform β (KIF1Bβ) gene. Further, we demonstrated that KIF1Bβ plays a tumour suppressive role in HCC in vitro and in vivo. Mechanistically, KIF1Bβ interacts with the cargo Fibulin-5 and mediates its intracellular anterograde transport and extracellular secretion, therefore, reducing the activation of the integrin pathway. We further identified the functional causative variant rs61784580 at 1p36.22, which is located in the promoter of KIF1Bβ and regulates its expression in an allele-specific manner. Finally, we observed that downregulation of KIF1Bβ sensitises HCC cells to integrin αv inhibitor cilengitide. CONCLUSIONS: Our findings shed light on the genetic and molecular mechanisms of the HCC-associated susceptibility locus at 1p36.22 and provide potential new strategies for the treatment of HCC.
引用
- Gao C, Wang Y, Zhou G, et al. KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway. Gut. 2026. PMID: 41087058. doi:10.1136/gutjnl-2025-336230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。